Expanding Therapeutic Utility of Carfilzomib for Breast Cancer Therapy by Novel Albumin-coated Nanocrystal Formulation

Carfilzomib (CFZ) is the second-in-class proteasome inhibitor with much improved efficacy and safety profiles over bortezomib in multiple myeloma patients. In expanding the utility of CFZ to solid cancer therapy, the poor aqueous solubility and in vivo instability of CFZ are considered major drawbac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Control Release
Main Authors: Park, Ji Eun, Park, Joonyoung, Jun, Yearin, Oh, Yunseok, Ryoo, Gongmi, Jeong, Yoo-Seong, Gadalla, Hytham H., Min, Jee Sun, Jo, Jung Hwan, Song, Myung Geun, Kang, Keon Wook, Bae, Soo Kyung, Yeo, Yoon, Lee, Wooin
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6638563/
https://ncbi.nlm.nih.gov/pubmed/30954620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2019.04.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados